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ABSTRACT	 	Nausea	and	emesis	are	two	major	concerns	for	patients	undergoing	chemotherapy	for	cancer.	The	5HT3	receptors	antagonist	ondansetron	is	the	major	factor	for	preventing	and	treatment	for	CINV	either	alone	or	often	 is	 combination	 with	 dexamethasone.	 Even	 these	 treatment	 options	 exist,	 CINV	 remind	 as	 major	adverse	event	for	all	chemotherapeutic	agents.	The	adverse	events	have	major	impact	on	patients	quality	of	life	and	compliance	with	treatment.	Aprepitant,	a	novel	neurokinin-1	(NK-1)	antagonist	has	been	introduced	as	a	new	class	of	drug	to	prevent	CINV.	Many	trials	and	studies	reveals	that	comparison	of	aprepitant	to	the	standard	ondansetron	and	dexamethasone	is	superior	in	protecting	against	CINV.	Here	this	study	evaluate	and	reveals	the	use	and	benefits	of	aprepitant	in	the	management	of	CINV.	
Keywords:	Aprepitant;	Chemotherapy;	Neurokinin-1;	Nausea;	Vomiting.	
ISSN: 2582-0672 
Research Article	
Corresponding	Author	Name:	Dr.	Robin	George	Email:	dhanyadharman07@gmail.com	
Article	Info	Received	on:	05-09-2019	Revised	on:	10-09-2019	Accepted	on:	14-09-2019	
DOI: https://doi.org/10.33974/ijrhcp.v2i1.147  
 
Copyright© 2019, Robin George, et al. Aprepi-
tant, a novel neurokinin-1 receptor antagonist in 
management of chemotherapy induces nausea 
vomiting (CINV) in cancer patients, Production 
and hosting by Rubatosis Publications. All rights 
reserved.	
CANCER	THE	GROWING	TISSUE	Cancer	describes	the	disease	that	result	when	cellular	changes	 cause	 uncontrolled	 growth	 and	 division	 of	cells,	the	term	‘neoplastic’	a	synonym	of	cancer	which	means	 ‘new	growth’.	The	meaningful	definition	of	a	neoplasm	or	tumour	is	‘a	mass	of	tissue	formed	as	a	result	of	abnormal,	excessive,	uncontrolled,	autono-mous	and	purposeless	proliferation	of	cells	even	after	the	cessation	of	the	stimulus	to	growth	which	caused	it[1].	In	the	most	basic	term,	cancer	refers	to	calls	that	grow	out	of	control	and	invade	other	tissue.	Cells	are	
capable	of	detect	and	repair	DNA	damage,	 if	cells	 is	severely	damaged	and	cannot	repair	itself,	it	usually	undergoes	programmed	cell	death	so	called	apopto-sis,	cancer	occurs	when	damaged	cells	grows,	divide	and	spread	abnormally	instead	of	self-destructing	as	they	should[2].		In	United	States,	 an	estimate	of	15.5	million	people	with	a	history	as	of	Jan	1,	2016,	according	to	the	2018	report	from	the	American	cancer	society[3].	There	are	many	 causes	 of	 cancer	 and	 over	 genetics’	 most	 of	them	are	preventable.	Cancer	is	the	2nd	leading	cause	of	death	in	United	States[4].	There	are	many	causes	of	cancer	and	some	of	them	are	preventable	smoking,	heavy	alcoholism,	obesity,	physical	 activity,	 poor	 nutrition	 etc.	 Genetics	 influ-ence	the	cell	production	of	protein,	and	proteins	that	carry	many	of	the	instruction	for	cellular	growth	and	division.	Cancer	is	more	curable	when	detected	early,	although	 some	 cancers	develop	 completely	without	symptoms,	or	the	symptoms	are	non-specific.	Cancer	treatment	 advances	 every	 year	 and	 early	 detection	has	made	many	cancers	treatable.	Cancer	symptoms	and	signs	are	also	depend	on	the	size	and	location	of	the	cancer	as	well	as	the	presence	or	absence	of	me-tastasis.		Cancer	can	occur	anywhere	in	the	body	either	on	ep-ithelial	or	non-epithelial	tissue	as	well	as	connective	tissues	 broadly	 cancer	 can	 classified	 as	 either	 solid	(ex:	breast,	 lung,	prostate)	or	 liquid	(blood,	 lymph).	Even	 the	 cancer	 can	 further	 classified	 according	 to	
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the	tissue	which	they	arise	like,	carcinoma,	sarcoma,	myeloma,	leukaemia	etc.		
Chemotherapy	 and	 chemotherapy	 induced	 nau-
sea	vomiting	Chemotherapy	works	against	 cancer	by	killing	 fast-growing	cancer	cells.	It	is	a	type	of	cancer	treatment	that	uses	drug	to	kill	cancer	cell.	It	works	by	stopping	or	 slowing	 of	 cancer	 cells,	 which	 grow	 and	 divide	quickly.	 Chemotherapy	 is	 the	 primary	 strategy	 for	malignancy	with	a	tendency	to	spread	throughout	the	body	and	advanced	cancers	that	have	metastasized.	Nearly	70%	cancer	patients	have	undergone	chemo-therapy.	If	there	were	no	effective	interventions,	the	incidence	of	nausea	and	vomiting	after	chemotherapy	would	be	as	high	as	70–80%	[5],	which	was	clinically	called	 chemotherapy-induced	 nausea	 and	 vomiting	(CINV).	 Although	 not	 life-threatening,	 these	 symp-toms	have	been	 ranked	as	 the	 two	of	 the	most	dis-tressing	 side	 effects	 affecting	 cancer	 patient’s	well-being	and	overall	response	to	chemotherapy	.Chemo-therapy	regimen	and	inter-individual	differences	are	the	most	critical	 factors	affecting	the	frequency	and	extent	of	CINV.	CINV	not	only	 reduces	 the	patient’s	tolerance	 to	 chemotherapy,	 prevents	 the	 treatment	from	completing	on	time	or	even	stops	therapy	[6],	but	also	 causes	 anorexia,	 nutritional	 deficiencies,	 and	even	 water	 and	 electrolyte	 disorders	 [7],	 which	 di-rectly	 affect	 the	 patients’	 short-term	 efficacy	 and	quality	 of	 life.	 A	 variety	 of	 neurotransmitters	 and	their	 receptors	 is	 involved	 in	 the	 development	 of	CINV.	At	 present,	 a	 combination	 of	 peripheral,	 cen-tral,	psychological	and	sensory	factors	is	known	to	be	associated	 with	 CINV,	 but	 the	 underlying	 mecha-nisms	remain	mostly	unclear	[5]		
Table 1: Classification of CINV (Chemotherapy induced 
nausea and vomiting 
Types	of	
CINV	 Description	
Acute	 Nausea	and/or	vomiting	occurring	within	24	hours	of	chemotherapy	ad-ministration.	
Delayed	 Nausea	and/or	vomiting	occurring	at	least	24	hours	post	chemotherapy	ad-ministration;	often	peaks	between	48	and	72	hours.	
Break-
through	
Nausea	and/or	vomiting	that	occur	within	5	days	post	chemotherapy	de-spite	optimal	antiemetic	c	regimen	used;	requires	rescue	therapy	with	other	antiemetics.	
Refrac-
tory	
Nausea	and/or	vomiting	that	occurs	in	subsequent	chemotherapy	cycles	despite	maximum	antiemetic	proto-col.	
Anticipa-
tory	
Nausea	and/or	vomiting	that	is	trig-gered	by	sensory	stimuli	associated	with	chemotherapy	administration.	
Management	of	CINV	Effective	antiemetic	regimens	for	highly	and	moder-ately	 emetogenic	 chemotherapy	 or	 radiotherapy	have	historically	been	based	on	the	combination	of	a	serotonin	 antagonist	 and	 a	 corticosteroid,	 as	 re-flected	in	numerous	antiemetic	treatment	guidelines	[5,8].	This	combination	is	highly	effective	for	the	con-trol	 of	 acute	 emesis	but	 less	 so	 for	delayed	 emesis,	and	the	contribution	of	serotonin	antagonists	to	the	management	of	delayed	emesis	has	been	questioned.	It	is	thus	imperative	that	feasible	and	effective	regi-mens	be	developed	that	address	both	acute	and	de-layed	 nausea	 and	 vomiting.	 Although	 these	 treat-ments	effectively	enhance	the	control	of	acute-phase	CINV,	it	still	should	pay	more	attention	to	the	control	of	delayed-phase	CINV.	Ondansetron	was	the	first	US	food	and	drug	admin-istration	(FDA)-	approved	5HT3	antagonist	in	1991.	Ondansetron	is	the	one	of	the	medications	most	com-monly	 used	 for	 empiric	 treatment.	 It	 is	 considered	first-line	therapy	for	the	treatment	of	chemotherapy	and	radiotherapy	induced	nausea	and	vomiting.	On-dansetron	 is	 the	 5HT3	 receptor	 antagonist	 used	 to	treat	and	prevent	chemotherapy-induced	nausea	and	vomiting	and	radiotherapy-induced	nausea	and	vom-iting.	 It	 appears	 on	 the	World	 Health	 Organization	(WHO)	 list	 of	 essential	medicines,	which	 is	 a	 list	 of	medications	that	considered	being	the	most	effective	and	safe	with	regards	to	meeting	the	most	important	needs	 in	a	health	 system.	Other	antiemetic	 that	ap-pear	 on	 this	 list	 with	 ondansetron	 include	 dexa-ethasone.	 In	 2006,	 the	 brand	 name	 version	 of	 on-dansetron	was	the	20th	highest	–	selling	brand-name	drug	in	the	United	States,	and	its	popularity	continues	today.	Ondansetron	has	extreme	utility	as	an	antie-metic	drug,	 and	 it	 is	 effective	 against	prevention	of	chemotherapy	induced	nausea	and	vomiting	and	ra-diation	induced	nausea	and	vomiting[7].		The	development	of	5HT3	antagonist	has	been	a	ma-jor	step	forward	in	the	prevention	and	treatment	of	chemotherapy	 –	 induced	 nausea	 and	 vomiting	(CINV).	These	agents	had	been	widely	regarded	as	the	most	 efficacious	 and	 antiemetic	 available	 until	 re-cently	and	have	been	recommended	for	several	years,	often	 in	 combination	 with	 corticosteroids,	 as	 the	agents	of	first	choice	to	control	nausea	and	vomiting	in	most	instances.	Despite	these	existing	preventative	measures,	CINV	remains	a	major	adverse	events	can	have	 a	major	 impact	 to	 patients	 quality	 of	 life	 and	compliance	 with	 treatment,	 and	 represent	 a	 major	therapeutic	 challenge	 that	 potentially	 threatens	 the	success	of	therapy.	Neurokinin	1	receptor	antagonist	is	one	of	the	classes	of	the	drug	used	to	suppress	nausea	and	vomiting	in	patients	 associated	 with	 cancer	 chemotherapy.		Aprepitant,	a	novel	neurokinin-1	antagonist,	has	been	recently	introduced	as	a	new	class	of	drugs	available	to	 prevent	 CINV.	 It	 is	 always	 used	 in	 combination	
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with	other	antiemetic	agents.	Aprepitant	is	indicated	for	the	prevention	of	acute	and	delayed	nausea	and	vomiting	associated	with	initial	and	repeat	courses	of	highly	 emetogenic	 cancer	 chemotherapy.	 Phase	 III	clinical	trials	in	patients	receiving	highly	emetogenic	cisplatin-based	chemotherapy	as	well	as	 in	patients	receiving	 moderately	 emetogenic	 chemotherapy	have	shown	that	apprepitant,	in	combination	with	a	5HT3	 receptor	 antagonist	 and	 dexamethasone	 pro-vides	 superior	 protection	 against	 CINV	 compared	with	standard	therapy	alone	with	preventative	regi-mens.	Aprepitant	has	been	proven	effective	not	only	for	acute	CINV,	but	also	for	delayed	CINV[5].	A	 combination	 of	 a	 serotonin	 antagonist,	 a	 cortico-steroid,	and	an	NK-1	antagonist	has	proven	effective	against	this	problem.	Aprepitant,	a	novel	neurokinin-1	(NK-1)	antagonist,	has	been	recently	introduced	as	a	new	class	of	drugs	available	to	prevent	CINV.	
Table 2: Treatment guidelines for CINV 
Emetic	
risk	 Treatment	regimen	
High	
Day	1:	NK1	antagonist	+	5HT3	antago-nist	+	Dexamethasone	Day	2-3:	NK1	antagonist	(if	using	Aprepitant)	+	dexamethasone	Day	4:	Dexamethasone	
Moder-
ate	
Day	1:	5HT3	antagonist	(palonosetron	preffered	)	+	dexamethasone	+_Nk1	an-tagonist	Day	2-4:	5HT3	antagonist	(if	did	not	use	palonosetron	preffered)	or	dexa-methasone	or	Aprepitant	+	dexame-thasone	+_	5HT3	antagonist.	If	Aprepi-tant	used	on	day	1,	days	2-3	aprepitant	+_dexamethasone	on	days	2-4	+_loraze-pam	
Mild	 Metoclopramide,	dexamethasomne,	or	prochlorperazine	+_	lorazepam.	
Mini-
mal	 No	routine	prophylaxis.	However,	the	key	question	in	this	setting	is	whether	apprepitant	 should	 be	 a	 part	 of	 the	 antiemetic	prophylaxis	.	The	ASCO	and	MASSC	guidelines	recom-mend	 the	 triple	 combination	 (a	 5HT3	 RA,	 dexame-thasone,	and	apprepitant)	 for	patients	receiving	the	cisplatin	 –based	 chemotherapy.	 The	 NCCN	 guide-lines,	 however,	 broaden	 the	 spectrum	of	 the	 use	 of	apprepitant	in	this	setting	and	advice	use	in	selected	patients	 receiving	 other	 chemotherapies	 of	 moder-ately	 emetogenic	 risk.	 Dexamethasone	 is	 the	 pre-ferred	agent	to	use	for	delayed	CINV	with	moderately	emetogenic	 chemotherapy.	 Nonetheless,	 When	aprepitant	 is	used	 for	 the	prevention	of	acute	CINV	then	 it	 should	 be	 used	 for	 prophylaxis	 of	 delayed	CINV	as	monotherapy,	 as	 stated	by	 the	MASCC	 and	ASCO	guidelines	suggest	aprepitant	with	or	without	dexamethasone	 in	 this	situation.	A	5HT3	RA	can	be	
used	as	an	alternative,	although	their	therapeutic	role	in	the	delayed	phase	is	rather	limited.	
CONCLUSION	Anti-emetic	treatment	guidelines	have	indicated	that	5HT3	receptor	antagonists	(RAs)	effectively	prevent	and	control	CINV	during	the	acute	phase	in	patients	receiving	chemotherapy	however,	they	are	less	effec-tive	in	preventing	CINV	in	the	delayed	phase.	Aprepi-tant	 is	a	potent	and	selective	neurokinin	1	receptor	antagonist	 that	 has	 been	 effective	 against	 CINV	 in	both	acute	and	delayed	phase	when	added	to	a	stand-ard	 antiemetic	 regimen	 (a	 5HT3	 RA	 and	 dexame-thasone)	 in	 patients	 receiving	 chemotherapy.	 The	NK-1	receptor	antagonist	aprepitant	has	been	shown	to	markedly	improve	control	of	delayed	emesis	after	both	highly	and	moderately	emetogenic	chemother-apy.	Of	interest,	aprepitant	also	improves	control	of	acute	emesis	when	used	in	combination	with	a	sero-tonin	antagonist	and	a	corticosteroid.	
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